Anti-CEA chimeric antigen receptor tumour cell therapy - TNK Therapeutics

Drug Profile

Anti-CEA chimeric antigen receptor tumour cell therapy - TNK Therapeutics

Alternative Names: CAR-T CEA; CEA CART

Latest Information Update: 13 Jun 2016

Price : $50

At a glance

  • Originator BDL Products, Inc.; CARgenix Holdings LLC
  • Developer TNK Therapeutics
  • Class CAR-T cell therapies
  • Mechanism of Action Carcinoembryonic antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 07 Jun 2016 TNK Therapeutics and 3SBio enter into a joint venture agreement to develop and commercialise CART cell based therapeutics
  • 10 Aug 2015 Phase-I clinical development in Cancer in USA (Parenteral)
  • 07 Aug 2015 TNK Therapeutics, a wholly-owned subsidiary of Sorrento Therapeutics, acquires BDL Products and CARgenix (Sorrento Therapeutics 8-K, August 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top